20 results about "Mycosis" patented technology

To provide a therapeutic and / or prophylactic agent for mycosis, which is excellent in safety and effectiveness, is administered to a Japanese mycosis patient, and contains isavuconazole or a prodrug thereof as an active ingredient.SOLUTION: A therapeutic and / or prophylactic agent for mycosis, which is administered according to a loading dosing regimen, and further administered according to a maintenance dosing regimen after a lapse of 12 to 24 hours from the end of the loading dosing regimen. (1) Loading dosing schedule: a dosing schedule in which isavuconazole or a pro-drug thereof is administered in 200mg by oral administration or intravenous drip infusion every 8 hours for a total of 6 times (2) Maintenance dosing schedule: a dosing schedule in which isavuconazole or a pro-drug thereof is administered in 200mg by oral administration or intravenous drip infusion once a day in terms of isavuconazole per dose.SELECTED DRAWING: Figure 1

The invention discloses a construction method of a novel composite biocontrol flora for preventing and treating cotton verticillium wilt, and relates to the technical field of biological prevention and treatment of agricultural plant diseases. The bacillus polymyxa and the bacillus cereus with the optimal antagonistic activity are respectively screened out through plate confrontation and buckling tests, and the bacillus pseudomycoides is obtained through screening by taking the growth promoting capability of dissolving phosphorus and producing indoleacetic acid as indexes. Through pairwise cross culture verification, the three strains are completely compatible and have no mutual inhibition effect. The method comprises the following steps: respectively and independently activating the three strains, carrying out enlarged culture, preparing single bacterial liquid with the OD600 value of 1.0, and uniformly mixing according to a volume ratio, so as to obtain the novel composite biocontrol flora for preventing and treating the cotton verticillium wilt. According to the invention, antagonistic bacillus and growth-promoting bacillus with complementary functions are screened, single bacteria are independently cultured and then are compounded according to a ratio of 1: 1: 1 to construct a composite flora, so that the synergistic interaction of efficient prevention and control of cotton verticillium wilt, cotton growth promotion and soil phosphorus solubilization is realized.

The application discloses a kind of multiple qPCR detection primer combinations of superficial mycosis pathogen, it includes the specific primer and probe of detecting Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, Microsporum canis, Microsporum audouinii, Microsporum gypseum, Candida albicans, Malassezia furfur;The application detects pathogen target gene using real-time fluorescent quantitative PCR technology;The method has the advantages of short time consumption, high specificity, low cost, and can detect multiple pathogens at a time, provides a convenient method for the detection of superficial mycosis pathogen, and has important significance for the early molecular diagnosis of superficial fungal infection patients.

The present invention relates to the cosmetic use of phytosterols to protect and / or restore the skin microbiota and / or to prevent and / or reduce the unsightly, unpleasant, and / or uncomfortable manifestations of skin microbiota alteration. It further relates to a cosmetic treatment method comprising the topical application of phytosterols to at least one area of ​​skin, advantageously the scalp, to protect and / or restore the skin microbiota and / or to prevent and / or reduce the unsightly, unpleasant, and / or uncomfortable manifestations of skin microbiota alteration.Finally, it concerns phytosterols for their use in the treatment and / or prevention and / or reduction of the occurrence of a pathology associated with an alteration of the skin microbiota, in particular chosen from the group consisting of acne, psoriasis and bacterial and / or fungal infections, ulcers, herpes, boils, folliculitis, abscesses, sycosis, impetigo, ecthyma, erysipelas, mycoses such as candidiasis or dermatophytoses such as ringworm and / or scabies, pigmentary and / or acne scars as well as their combinations and / or in the treatment and / or prevention of superinfection of wounds and / or in the prevention of spots.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a compound ointment preparation for treating fungal infection and a preparation method and application thereof. According to the compound ointment preparation, chlortetracycline hydrochloride, econazole nitrate and triamcinolone acetonide compound serve as core components, no chemical incompatibility exists among chlortetracycline hydrochloride, econazole nitrate and triamcinolone acetonide, and comprehensive treatment on external auditory canal mycosis is achieved through the pharmacological synergistic effect. Meanwhile, adaptive plant essential oil is specially selected, and the proportion of active ingredients is optimized, so that the compound ointment preparation can effectively control bacteria, fungi and inflammation, the hormone amount is obviously reduced, and side effects are reduced.

The invention belongs to the technical field of probiotic screening and application, and particularly relates to lactobacillus rhamnosus for preventing and treating livestock and poultry mycosis and application of the lactobacillus rhamnosus. The lactobacillus rhamnosus is separated from intestinal tracts of healthy chickens and is preserved in China Center for Type Culture Collection in Wuhan University in China on February 27, 2025, and the preservation number of the lactobacillus rhamnosus is CCTCC NO: M2025309. The strain has remarkable inhibition and detoxification effects on various moulds and toxins thereof, can be added into animal medicines, animal feeds, feed additives and feed leavening agents, and has a wide application prospect.

A test device, such as a lateral flow device, for detecting the presence of two or more biomarkers selected from the group consisting of fungal, viral and / or bacterial biomarkers, in a liquid sample, wherein the presence of at least one of the biomarkers is detected at two or more different concentrations in the sample. The device is particularly useful in the diagnosis of sepsis and / or the selection of treatment for a subject suspected of having sepsis.

The present invention relates to the field of image recognition technology, and specifically to a method for delineating fungal lesions in fungal keratitis under a microscope, comprising: obtaining microscopic images of the epithelium, stroma, and endothelium at different depths of a corneal sample; analyzing the influence range of fungal spores based on the grayscale distribution characteristics of the microscopic image of the epithelium to obtain a connected domain of pending lesions in the epithelium; analyzing the interweaving of highlight portions based on the edge distribution characteristics of the microscopic image of the stroma to obtain a connected domain of pending lesions in the stroma; analyzing the regularity and permeability of cells based on the transparency characteristics of the microscopic image of the endothelium to obtain a connected domain of pending lesions in the endothelium; and fusing the connected domains of the pending lesions of the epithelium, stroma, and endothelium to delineate the fungal lesion area corresponding to the corneal sample. The present invention can avoid the influence of nerve fibers on fungal lesion identification and improve the accuracy of fungal lesion delineation results.

The invention provides lactobacillus plantarum NX87 and application thereof, the lactobacillus plantarum NX87 is lactobacillus plantarum NX87, the lactobacillus plantarum NX87 is preserved in the Guangdong Microbial Culture Collection Center on April 23, 2025, the address is No.59 building, No.100 courtyard, Xianlie Middle Road, Guangzhou, and the preservation number is GDMCC No. 66203; the lactobacillus plantarum NX87 is used for preventing and treating the streptococcus suis, the escherichia coli and the balloon mycosis, and the lactobacillus plantarum NX87 is used for preventing and treating the streptococcus suis, the escherichia coli and the balloon mycosis. The strain disclosed by the invention has relatively strong inhibition capability on streptococcus suis, escherichia coli and balloon mycosis, has relatively strong tolerance to acid, has good cholate tolerance, and is beneficial to colonization at parts such as intestinal mucosa and the like.

The invention discloses a dimethachlon nano-scale microcapsule and bacillus amyloliquefaciens combined medicament as well as a preparation method and application of the dimethachlon nano-scale microcapsule and bacillus amyloliquefaciens combined medicament. According to the invention, a design thought that a protein base is used as a carrier to prepare a nano-scale microcapsule is adopted, and amphiphilic zein and modified vital gluten are used as main materials of the nano-carrier. And n-butyl alcohol is taken as a cosurfactant, so that the effects of reducing the HLB (Hydrophile-Lipophile Balance) value of the emulsion and adjusting the interfacial tension are achieved. Meanwhile, the bacillus amyloliquefaciens MLY71 is matched, so that the control effect of the dimethachlon on fungal pathogenic bacteria is improved, the application amount of the dimethachlon is reduced, and the residual toxicity of the dimethachlon on soil is reduced.

The invention relates to the use of kahalalide-type depsipeptide compounds of formulae I and / or II, obtained from the green alga Pedobesia sp., for controlling a broad spectrum of fungal plant pathogens. The invention also encompasses fungicidal compositions comprising said compounds with a phytologically acceptable carrier, a process for their preparation from Pedobesia biomass, and their use for the preparation of a medicament for treating mycosis such as that caused by Candida albicans or Trichophyton rubrum.

The invention relates to the field of veterinary drugs, in particular to a pharmaceutical composition for preventing and treating rabbit dermatomycosis as well as a preparation method and application thereof. The pharmaceutical composition is prepared from the following raw materials in percentage by weight: 0.5%-2% of clotrimazole, 1%-5% of 5% gentamicin sulfate powder, 20%-40% of sulfur powder, 50%-75% of talcum powder, 2%-6% of 32.5% neomycin sulfate powder and the balance of water. According to the composition, clotrimazole is introduced as a core antifungal component, a targeting action mechanism of specific inhibition of fungal cytochrome P-450 of clotrimazole is utilized, and a non-specific bactericidal effect of sulfur powder is combined, so that synergistic interaction is realized.

A method of indicating the cause of a subject’s fever. The method comprises analysing gene expression in a sample in the subject with a fever. Based on this analysis ratio-based biomarkers (RBB) which are the ratio between expression of a numerator gene selected from one of (a) ANXA3, ALPL, IL1R2, ARG1, or MMP9, (b) IFIT1, RSAD2, IFIT3, HERC5, PI3, or ADGRE3, (c) ANKRD22, BATF2, ETV7, GBP5, SAERPING1, CEACAM8, CAMP, or LTF, (d) ANXA3, ALPL, IL1R2, ARG1, MMP9, FCER1A, CCR3, or HDC, (e) CEACAM8, (f) IFITM3, (g) IFIT1, RSAD2, IFIT3, LY6E, HERC5, PI3, ADGRE3, FCER1A, HDC, CCR3, or CCN3, (h) FCER1A, HDC, CCR3, CCR3, CCN3, or PI3, or (i) IFIT1, RSAD2, IFIT3, HERC5, PI3, or ADGRE3, and a denominator gene selected from SAT1, SRGN, or NCF1 is determined. Based on the comparison of these ratios, interferon activating disease, non-interferon activating disease, systemic fungal disease, a bacterial infection, Kawasaki disease, tuberculosis, a viral disease, and systemic lupus erythematosus is distinguished. The analysis can be in vitro. The sample representative of gene expression in a subject can comprise neutrophils or whole blood. A further aspect is a kit comprising reagents capable of binding to RNA, selected from primers and a probe.

Methods and compositions for treating, preventing and controlling fungal infections, including superficial infections, using compounds of the β-carboline class are disclosed. Pharmaceutical compositions comprising β-carbolines alone, or in combination with therapeutically effective amounts of an antimycotic, are administered to a subject to treat or prevent a superficial fungus infection such as those caused by fungi selected from the Candida or Trichophyton genus, infections such as dermatomycosis, diaper rash (yeast dermatitis), athletes' foot (tinea pedis), jock itch (tinea cruris), ringworm (tinea capitis) and cutaneous candidiasis. Methods of treating, preventing or controlling fungal infections in a plant are also disclosed, wherein a composition comprising an agriculturally acceptable amount of a β-carboline and a fungicide is administered to the plant and / or the locus of the plant, β-carbolines having the following formula are preferred. (Formula I).

A topical source of hydrogen sulfide for use in the treatment of nail infections, such as nail mycosis, is disclosed. A system comprising the localized source of hydrogen sulfide is also disclosed.

The invention discloses a primer group for simultaneously detecting eight pet dermatophytes and application of the primer group. The primer group comprises a forward PCR (Polymerase Chain Reaction) amplification primer, a reverse PCR amplification primer and a control primer sequence and a template of eight pet skin fungi, wherein the eight pet skin fungi comprise microsporum canine, microsporum gypsiformis, malassezia, megasporum, trichophyton mentagrophytes, trichophyton fibraureae, histoplasma capsulatum and globularia; the sequences of the primers are respectively shown as SEQ ID NO.1-SEQ ID NO.19. The primers can detect eight pet dermatomycosis, have very high sensitivity and specificity, have certain development, utilization and popularization values, and can provide technical support for clinical diagnosis of pet dermatomycosis.

The invention relates to the technical field of image recognition, in particular to a fungal focus sketching method for fungal keratitis under a microscope, which comprises the following steps: acquiring microscopic images of epithelium, matrix layer and endodermis of different depths of a cornea sample; analyzing the influence range of fungal spores according to the gray level distribution characteristics of the microscopic image of the epithelium, and obtaining an undetermined focus connected domain of the epithelium; analyzing the interweaving condition of the highlight part according to the edge distribution characteristics of the microscopic image of the matrix layer to obtain an undetermined focus connected domain of the matrix layer; analyzing regularity and permeability of cells according to transparency characteristics of the microscopic image of the endodermis to obtain a to-be-determined focus connected domain of the endodermis; fusing the to-be-determined focus connected regions of the epithelial layer, the matrix layer and the endothelial layer, and sketching a fungal focus region corresponding to the cornea sample. The influence of nerve fibers on fungal lesion recognition can be avoided, and the accuracy of a fungal lesion sketching result is improved.

The application belongs to the technical field of screening and application of probiotics, and particularly relates to a lactobacillus rhamnosus for preventing and treating mycosis of livestock and poultry and application thereof. The lactobacillus rhamnosus is isolated from the intestinal tract of healthy chickens, and has been preserved in the China Center for Type Culture Collection of Wuhan University on February 27, 2025, with a preservation number of CCTCC NO: M2025309. The strain has significant inhibitory and detoxification effects on various molds and their toxins, and can be added to animal medicines, animal feeds, feed additives and feed leavening agents, and has a broad application prospect.

This invention provides a compound called *Paris polyphylla* saponin A, its pharmaceutical composition, preparation method, and application, belonging to the fields of pharmaceutical technology and cosmetic technology. It provides *Paris polyphylla* saponin A, as well as *Paris polyphylla* saponins A-D and *Paris polyphylla* saponin A in the preparation of drugs for the prevention and treatment of superficial fungal infections of the skin. The above compounds are effective against *Trichophyton rubrum* (…). Trichophyton rubrum Epidermophyton floccosum ( Epidermophyton floccosum ) and Microsporum gypseum ( Microsporum gypseum It has a significant inhibitory effect on dermatophytes such as dermatophytes and can be used to prepare drugs for the prevention and treatment of superficial fungal infections of the skin.

The invention relates generally to the treatment of onychomycosis and, more particularly, to the treatment of onychomycosis using compositions comprising trichostatin A (TSA) and compositions for use in such methods.